NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.54 against a street estimate of 3.60 — a miss of 85.0%.
with an average price target of ₹968.67.
MIXED Q1 FY27 shows 15% YoY revenue growth to ₹304cr and EBITDA improvement to ₹25cr, but management cautious on margin recovery timing. Two major capex projects (7-ACA, Cefiderocol) remain on track for FY27-28 launches, offsetting near-term cephalosporin pricing pressure. Q1 FY27 Russia licensing deal announced July 2026 with 1.5–2yr registration/launch timeline. Europe (Exblifep) showing accelerating vials growth via Advanz Pharma in Big 5 markets plus Nordic; Eastern Europe B2B partnerships pending. MEA registration complete in South Africa, GCC coverage achieved, but commercial rollout postponed due to regional conflict. Analysts pressed on margin recovery timing (uncertain, H2-dependent), 7-ACA dumping risk (management argues Chinese firms now profit-driven, pricing stable), and Exblifep revenue contribution (long-term, no near-term milestones). Management was transparent on competi…
Full summary in the app.
| Holder | Stake |
|---|---|
| Quant Mutual Fund - Quant Small Cap Fund | 5.79% |
| Kotak Mahindra Trustee CO Ltd A/C Kotak Consumption Fund & 7 Others With Same Pan | 3.99% |
| Uti-healthcare Fund & 3 Others With Same Pan | 3.10% |
| Invesco India Contra Fund & 1 Other With Same Pan | 2.41% |
| Bandhan Small Cap Fund & 5 Others With Same Pan | 1.06% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call ORCHID PHARMA LIMITED – Q1 FY27 EARNINGS CALL SUMMARY August 21, 2026 --- HEADLINE NUMBERS • Q1 FY27 Revenue: INR 304 crores (up 15% YoY from INR 2 | 2026-08-24 |
| Investor presentation · Q1 FY27 | 2026-08-20 |
| Quarterly results · Q1 FY27 ORCHID PHARMA LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Full Year FY2026 Standalone Net Sales: ₹1,23,277.84 lakhs (down fr | 2026-08-14 |
| Q4 FY26 earnings call ORCHID PHARMA LIMITED – Q4 FY'26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY'26 Revenue: INR 238 crores (vs INR 237 crores in Q4 FY'25) – broadly stab | 2026-06-01 |
| Investor presentation · Q4 FY26 ORCHID PHARMA LIMITED - INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue: ₹811 Cr (down 12% vs FY25: ₹922 Cr) • FY26 EBITDA: ₹101 Cr (down 36% vs FY | 2026-05-26 |
| Quarterly results · Q4 FY26 ORCHID PHARMA LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Full Year FY2025-26 Standalone Net Sales: ₹81,132.73 lakhs (declin | 2026-05-25 |
| Q3 FY26 earnings call ORCHID PHARMA LIMITED – Q3 FY'26 DOCUMENT SUMMARY HEADLINE NUMBERS • Q3 FY'26 sales: INR 207 crores vs INR 217 crores in Q3 FY'25 (5% YoY decline) • | 2026-02-16 |
| Quarterly results · Q3 FY26 ORCHID PHARMA LIMITED – FINANCIAL SUMMARY Q3 & 9M FY2025-26 (Period Ended December 31, 2025) --- HEADLINE NUMBERS • Q3 FY2026 Net Sales: Rs 20,726. | 2026-02-11 |
Readable in the app.
| Announcement | Date |
|---|---|
| Trading approval of equity shares issued under scheme of amalgamation Orchid Pharma Limited has completed the listing of 4.46 crore newly issued equity shares on NSE and BSE, effective September 23, 2026. These shares were allotted as part of a scheme of amalg | 2026-09-23 |
| Allotment of securities pursuant to Scheme of Arrangement/Amalgamation Orchid Pharma Limited has allotted (distributed) approximately 44.6 million securities to shareholders as part of a Scheme of Arrangement or Amalgamation. This decision was made at a company | 2026-08-01 |
| Record date set for merger/hive-off transaction Orchid Pharma Limited has informed the Exchange that Record date for the purpose of Merger/HiveOff is 23-Jul-2026. | 2026-07-10 |
| Board noted effect of Scheme of Amalgamation Outcome of the Board Meeting: Noting the effect of Scheme of Amalgamation | 2026-07-10 |
| NCLT approves scheme of amalgamation and arrangement with another company Orchid Pharma Limited has received approval from the National Company Law Tribunal (NCLT) in Chennai on June 5, 2026 for its merger with Dhanuka Laboratories Limited. This is the key regulat | 2026-06-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Orchid Pharma Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.